Last reviewed · How we verify
Dextrofenfluramine (DEXFENFLURAMINE)
At a glance
| Generic name | DEXFENFLURAMINE |
|---|---|
| Drug class | dexfenfluramine |
| Target | Alpha-1B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Obesity
Common side effects
Drug interactions
- isocarboxazid
- phenelzine
- selegiline
- tranylcypromine
Key clinical trials
- Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (PHASE2)
- Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |